Travere presents long-term FILSPARI data at European kidney conference

June 4, 2026 10:09 AM

Travere Therapeutics (NASDAQ: TVTX) presented extended results from its Phase 3 DUPLEX study of FILSPARI at the European Renal Association ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found